ORKA Oruka Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 907654 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-18.1%
ROA-17.5%
ROIC (approx.)-20.6%
Asset turnover—
Leverage & solvency
Liabilities / assets2.8%
Debt / equity0.00x
Current ratio29.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $53.70M | $43.26M | $29.14M | $27.64M | $28.99M | $24.09M | $19.93M | $25.69M |
| SG&A expense | $8.44M | $6.85M | $7.29M | $6.79M | $5.12M | $4.34M | $5.16M | $3.76M |
| Operating income | -$62.14M | -$50.11M | -$36.43M | -$34.43M | -$34.10M | -$28.43M | -$25.09M | -$29.45M |
| Interest expense | — | — | — | — | — | — | — | $504,000 |
| Net income | -$49.97M | -$41.21M | -$31.82M | -$29.58M | -$30.28M | -$24.57M | -$21.00M | -$28.62M |
| EBITDA | -$62.09M | -$50.06M | -$36.39M | -$34.40M | -$34.09M | -$28.41M | -$25.07M | — |
| EPS (basic) | — | — | — | — | — | -0.46 | -0.40 | -1.46 |
| EPS (diluted) | — | — | — | — | — | -0.46 | -0.40 | -1.46 |
| Weighted avg. shares (diluted) | — | — | — | — | — | 42.10M | 41.68M | 15.01M |
| Balance sheet | ||||||||
| Cash & equivalents | $191.52M | $268.47M | $49.52M | $46.94M | $91.25M | $65.40M | $83.57M | $410.88M |
| Short-term investments | $728.76M | $605.09M | $339.31M | $290.11M | $257.90M | $263.01M | $265.52M | — |
| Current assets | $941.49M | $884.56M | $395.25M | $343.86M | $355.16M | $332.01M | $352.08M | $412.95M |
| PP&E, net | $309,000 | $275,000 | $318,000 | $288,000 | $253,000 | $174,000 | $159,000 | $160,000 |
| Total assets | $1.23B | $1.14B | $504.48M | $488.62M | $509.25M | $357.42M | $377.11M | $414.09M |
| Current liabilities | $31.78M | $22.97M | $16.63M | $15.37M | $20.97M | $12.11M | $11.72M | $18.04M |
| Total liabilities | $33.88M | $24.84M | $17.76M | $16.69M | $22.46M | $13.78M | $12.39M | $18.88M |
| Shareholders' equity | $1.20B | $1.11B | $486.72M | $471.93M | $486.79M | $343.64M | $364.73M | $342.37M |
| Shares outstanding | 67.23M | 61.07M | 50.17M | 48.72M | 48.38M | 37.45M | 37.44M | 35.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$44.33M | -$33.15M | -$23.58M | -$22.59M | -$21.60M | -$23.14M | -$20.87M | — |
| Capital expenditure | $83,000 | $0 | $73,000 | $63,000 | $99,000 | $34,000 | $13,000 | — |
| Free cash flow | -$44.41M | -$33.15M | -$23.65M | -$22.66M | -$21.70M | -$23.18M | -$20.88M | — |
| Investing cash flow | -$159.40M | -$410.95M | -$14.44M | -$22.02M | -$122.45M | $4.86M | $42.87M | — |
| Financing cash flow | $126.77M | $663.04M | $40.60M | $298,000 | $169.91M | — | — | — |
| Depreciation & amortization | $49,000 | $43,000 | $43,000 | $28,000 | $20,000 | $19,000 | $16,000 | — |
| Stock-based compensation | $9.13M | $7.28M | $6.97M | $4.12M | $10.16M | $5.08M | $4.88M | $9.00M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.